Natural history of anti-platelet antibody formation in patients with Glanzmann thrombasthenia: A French multicenter prospective study [0.03%]
Dominique Desprez,Roseline d&#x;Oiron,Sophie Voisin et al.
Dominique Desprez et al.
Background: Glanzmann thrombasthenia (GT) is a rare inherited platelet function disorder caused by defects in the ITGA2B or ITGB3 genes encoding the αIIbβ3 integrin. Repeated transfusions often lead to immunization agai...
A rapid point-of-care test for diagnosis of factor VIII inhibitors in haemophilia A patients [0.03%]
Shruti Kharat,Fiza Jivani,Kranti Patil et al.
Shruti Kharat et al.
Background: The development of neutralizing antibodies (NA) or inhibitors against exogenous factor VIII (FVIII) represents a major adverse event in haemophilia A (HA) treatment. The conventional assay for diagnosis of FVI...
Single-Domain Antibodies to Reverse the Effects of Factor Xa Inhibitors on Coagulation Tests [0.03%]
Junxiong Zhao,Ischa Hoornstra,Dana Huskens et al.
Junxiong Zhao et al.
Background: Direct oral anticoagulants (DOACs) interfere with coagulation assays, complicating thrombophilia and lupus anticoagulant diagnoses. Single-domain antibodies (sdAbs) may be used to neutralize anticoagulant effe...
Dysregulation of HIF-1α-regulated and thrombo-inflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms [0.03%]
BCR::ABL1阴性骨髓增生性肿瘤患者血栓风险可能与HIF-1α调节的促血栓和炎性基因失调有关
Olga Morath,Therese Wolfrum,Carl Crodel et al.
Olga Morath et al.
Background: Hypoxia-inducible factor-1α (HIF-1α) regulates multiple pathways involved in metabolism, inflammation, and coagulation and may contribute to thrombotic complications in patients with BCR::ABL1-negative myelo...
TQB3473, a Novel Spleen Tyrosine Kinase Inhibitor for Primary Immune Thrombocytopenia: A Single-Arm, Open-Label, Multicenter Phase 1 Study [0.03%]
新型脾酪氨酸激酶抑制剂TQB3473治疗原发性免疫性血小板减少症的单臂、开放标签、多中心Ⅰ期临床试验
Bingjie Ding,Tiejun Gong,Xiangzhou Du et al.
Bingjie Ding et al.
Background: Effective treatments for relapsed/refractory immune thrombocytopenia (ITP) remain limited. TQB3473, a novel oral spleen tyrosine kinase (SYK) inhibitor, was evaluated to address this unmet need. ...
The p.T216R mutation of the thromboxane A2 receptor disrupts platelet function by selectively altering the G12/23 signaling pathway [0.03%]
p.T216R突变通过选择性改变G12/23信号途径干扰血小板功能
Kevin Denis,Véronique Heim,Mathieu Fiore et al.
Kevin Denis et al.
Background: The thromboxane A2 receptor (TBXA2R) is a platelet receptor which binds to two distinct G protein signaling pathways (Gq and Gα12/13) and plays a major role in platelet activation. Mutations in the TBXA2R gen...
Development of New Antithrombotic Drugs for Children (Part 1): Guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group [0.03%]
新型儿童抗凝血药物研发（一）：国际抗栓协会小儿和新生儿血栓形成及止血亚专业委员会及Pedi-ATLAS小组的指导建议
Neil A Goldenberg,Scott D Berkowitz,Marisol Betensky et al.
Neil A Goldenberg et al.
An interactive human PROS1 variants database provides novel insights into the genetics and phenotypes of inherited protein S deficiency [0.03%]
互动的人类PROS1变异数据库为遗传性和获得性蛋白S缺乏的遗传和表型提供了新的见解
Zepeng Hou,Fangni Liu,Shixia Dong et al.
Zepeng Hou et al.
Background: The lack of an interactive PROS1 variant database has impeded efficient research on inherited protein S deficiency (PSD). Objectives: ...
Identifying Risk Factors for Major Bleeding in Patients with Atrial Fibrillation Using Direct Oral Anticoagulants: A Systematic Review and Meta-analysis [0.03%]
使用直接口服抗凝剂治疗的房颤患者发生大出血的风险因素的系统评价和 meta 分析
Xin Wang,Mang-Mang Pan,Jia Wang et al.
Xin Wang et al.
Background: Major bleeding (MB) remains a serious complication in atrial fibrillation (AF) patients treated with direct oral anticoagulants (DOACs), but effect estimates for individual factors vary across studies and have...
Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag versus romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) Cohort [0.03%]
法国成人免疫性血小板减少症（FAITH）队列中艾曲波帕与罗米司亭治疗原发性免疫性血小板减少成年患者血栓风险的比较：一种目标试验模拟方法
Jérémy Zordan,Yoann Zadro,Agnès Sommet et al.
Jérémy Zordan et al.
Background: Thrombopoietin receptor agonists (TPO-RAs) have been identified as a risk factor for thrombosis in immune thrombocytopenia (ITP). The possibility of a risk difference between eltrombopag and romiplostim (the o...